Articles tagged with Cancer Cells
Researchers from Goethe University Frankfurt discovered a novel biomarker, SAMHD1, that enables accurate prediction of therapy responders and non-responders in acute myeloid leukaemia (AML) patients. This biomarker can guide cytarabine-based chemotherapies to only those patients likely to respond, sparing others from toxic side effects.
Two studies reveal that cancer cells can tolerate genetic mutations by inactivating the BCL9L gene and slowing down division to avoid mistakes, allowing them to thrive and evolve. This understanding may lead to new ways to target cancer cells and improve treatment efficacy.
Scientists have discovered a unique 'gear' in the molecular motor protein KlpA that enables it to switch direction of movement, allowing chromosomes to be properly divided during cell division. This finding could lead to novel treatments for certain types of cancers.
Researchers aim to remove senescent cells, which accumulate with age, to regrow hair, improve organ function and combat aging. However, hurdles include safety issues, off-target effects and high costs, limiting translation to humans.
A combination of metformin and syrosingopine drives cancer cells to programmed 'suicide' by blocking their energy supply, inhibiting growth and inducing tumor cell death. The treatment shows promise for targeting the energy needs of tumor cells.
A study published in Nature discovered that fat utilization is required for the development and growth of lymphatic vessels, a key route for cancer cell spread. Researchers found that inhibiting fat usage can control lymphatic vessel growth, offering new avenues for preventing metastasis and treating complications like lymphedema.
Researchers discovered an obesity-linked protein FTO's role in leukemia cell growth, survival, and drug response. FTO modulates gene expression by altering RNA modification, leading to cancer-promoting effects.
Scientists from the Niels Bohr Institute have identified a new way to control the production of important proteins that regulate the immune system. The discovery could provide a new opportunity to fight diseases such as cancer, Alzheimer's, and diabetes by controlling the cell's genetic response.
A protein called Peroxiredoxin 1 (PRDX1) has been identified as a key player in protecting telomeres from oxidative damage. By analyzing the protein composition of telomeres across the cell cycle, researchers found that PRDX1 functions as an antioxidant enzyme, preserving telomeric DNA for extension by telomerase.
Researchers found that a high-fat, low-sugar diet for 72 hours prior to diagnostic imaging improved the accuracy of diagnosing cardiac sarcoidosis. This technique minimizes indeterminate findings and allows clinicians to better monitor patient progress under treatment.
Researchers at the Salk Institute have discovered that intermittent expression of genes normally associated with an embryonic state can reverse the hallmarks of old age. This approach resulted in the rejuvenation of mice with a premature aging disease, countering signs of aging and increasing their lifespan by 30%. The early-stage work...
A team of scientists from Helmholtz Zentrum München has isolated and characterized therapy-resistant leukemia cells, which are responsible for relapse in the disease. These cells can be eliminated using modern genetic engineering techniques, offering a new approach to prevent disease relapse.
Researchers found that KRAS mutant cancer cells form more stress granules in response to chemotherapy, making them harder to kill. A new compound target, 15-d-PGJ2, may help improve treatment outcomes by blocking this coping mechanism.
Researchers have developed a new technique to switch key biomolecules on and off, allowing them to study the effects of kinases as they work in living cells. This breakthrough could lead to the discovery of novel drug targets for cancer treatment.
Researchers at Ulsan National Institute of Science and Technology (UNIST) have made a groundbreaking discovery in cancer treatment. They developed novel Iridium(III) complexes that utilize red light to attack and kill cancer cells, providing a promising new approach for photodynamic therapy (PDT).
Researchers at La Jolla Institute for Immunology found that the loss of TET proteins hinders T cell maturation and promotes aberrant proliferation, leading to a lethal disease resembling lymphoma. The study's findings suggest that TET proteins serve as tumor suppressors and may help block malignancy in cancers marked by TET mutations.
Researchers at UT Southwestern Medical Center found that intermittent fasting inhibits the development and progression of acute lymphoblastic leukemia (ALL), a type of childhood leukemia. However, fasting was ineffective against another type of blood cancer commonly affecting adults, acute myeloid leukemia (AML).
Researchers have made a major discovery about how cells control when to divide, revealing a key part of the cellular machinery that prevents cells from dividing until DNA is properly aligned. This finding could lead to new treatments for cancer by forcing cancer cells into premature division and killing them.
Scientists have discovered a new class of compounds that can be used to target cancer cells with greater specificity. The technology uses naturally occurring enzymes to trigger the release of therapeutic payloads only at cancer sites.
Researchers have identified a new adaptor protein on the microtubule roadway that helps motors navigate proteins to their correct destinations. This discovery challenges previous assumptions about motor function and has implications for understanding diseases such as cancer and cardiac disease.
Researchers developed an artificial structure that can switch on immune cells to target and destroy cancer cells. The system mimics the cell membrane of antigen-presenting cells, which are responsible for activating immune responses against cancer.
The study found that KTE-C19 induced a significant response rate in patients with diffuse large B-cell lymphoma, with 76% overall response and 47% complete remission. Serious adverse events were reported, but the team developed guidelines to manage side effects across multiple institutions.
The latest ASCB celldance videos offer an immersive look at living cells through powerful imaging technologies. The three selected labs showcased their research using innovative storytelling methods, including spoken word and animation. The videos provide a glimpse into the intricate cellular dance of life.
A group of 12 high-risk acute myeloid leukemia patients who received genetically engineered immune cells are still in remission after over two years. The treatment was successful in recognizing and destroying cancer cells, with no relapse observed in this cohort.
A metabolite called D-2-hydroxyglutarate (D-2HG) has been identified as a promising target for future cancer therapies due to its ability to promote cancer cell transformation and increase the likelihood of tumor spread in colorectal cancer patients.
The discovery of EphA2 as a receptor for progranulin sheds light on its role in cancer and neurodegenerative diseases. Progranulin binding activates cellular pathways that promote cancer cell aggression, while also triggering a positive feedback loop that increases progranulin secretion.
Researchers identified a molecule called AXL which triggers the spread of an aggressive form of ovarian cancer. Blocking AXL may be an effective treatment option for patients with Mes subtype ovarian cancer.
Researchers at the University of York and Texas have identified a protein, PAQR11, in the Golgi apparatus that receives a signal from Zeb1, triggering the transport of membrane sacks and altering the cancer cell's perimeter. This process allows cancer cells to detach from their fixed position and travel to other parts of the body.
Researchers at the University of Southampton have engineered human cells with a genetic circuit that produces a molecule inhibiting HIF-1, allowing cancer cells to survive in nutrient-limited environments. The study demonstrates the potential for using sentinel circuits to target diseases like cancer.
A study published in Nature Cell Biology reveals a pro-growth signaling pathway common to many cancers that can be targeted with precision, leading to the efficient killing of cancer cells while leaving healthy cells unaffected. The researchers identified a scaffolding protein IQGAP1 as a key player in this pathway.
Researchers capture elusive DNA reaction intermediates in living cells, discovering mechanisms underlying genome instability and a new role for an E. coli protein related to human cancer proteins. This breakthrough could lead to the development of new drugs that prevent cancer by neutralizing these key pieces of genetic code.
Arecoline, an analog of nicotine, has been identified as an inhibitor of the enzyme ACAT1, which contributes to the Warburg effect in cancer cells. Researchers found that arecoline steers cells' metabolism away from glycolysis, inhibiting growth in human lung cancer and leukemia cells.
Restoring dysfunctional blood vessels in tumors can prevent cancer cells from spreading and improve chemotherapy delivery. Healthy tumor vessels also enhance the supply of immune cells, which is crucial for emerging immunotherapy treatments.
Scientists have established comprehensive maps of the human epigenome, revealing how genes are active in specific cells. The maps, published by the International Human Epigenome Consortium, provide insights into cellular differentiation and potential new treatments for diseases.
A new study by TSRI researchers suggests that disruptions in circadian rhythms may leave levels of an important cancer-linked protein, called cMYC, unchecked. This connection has significant implications for the link between daily rhythms and cell growth.
A study by the University of Leeds found that Reovirus, a common childhood cough virus, can stimulate the body's immune system to kill off liver cancer cells and the hepatitis C virus. The researchers hope to start clinical trials to test its effectiveness in treating primary liver cancer.
Researchers have developed a new cancer treatment called photoimmunotherapy that combines the immune system with laser energy to target and destroy cancer cells. This innovative technique delivers precise, lethal payloads with minimal collateral damage.
A multidisciplinary international team of scientists solved the mystery of ferroptosis, a type of controlled cell death that uses iron to safely destroy and recycle malfunctioning cells. The study aims to develop potential therapies for conditions like radiation injury, cancer and radiation-induced cellular damage.
Researchers at CHLA are developing a new treatment approach for patients with relapsed acute lymphoblastic leukemia (ALL) by targeting the molecule integrin alpha4, which shelters leukemia cells from chemotherapy. The goal is to develop a novel inhibitor of this molecule for clinical use.
A new 'sponge on a string' pill test has been shown to accurately identify people with Barrett's oesophagus who are at low risk of developing oesophageal cancer. This non-invasive test may replace uncomfortable endoscopies for some patients, allowing them to be monitored instead.
Researchers at the University of Pittsburgh Cancer Institute discovered that cancer cells exploit a previously unknown mechanism called alternative lengthening of telomeres (ALT) to reset their telomere clocks. This allows them to continue dividing and growing, making them more aggressive and resistant to treatment.
A systematic review of seven studies found that low vitamin D levels are associated with an increased risk of bladder cancer. Vitamin D deficiency may be a key factor in preventing the cells within the bladder from stimulating an adequate immune response to abnormal cells, suggesting a potential mechanism for cancer prevention.
Pitt researchers discovered how oxidative stress accelerates telomere shortening by damaging DNA precursor molecules. This finding offers a new way to inhibit telomerase activity, potentially treating cancer. The study also reveals that oxidative stress can promote telomere lengthening.
A team of researchers discovered that immune T cells have two internal clocks controlling their lifespan and division, shedding new light on how the body regulates immune responses. The discovery also explains how errors in these clocks may lead to immune cell cancers such as leukaemia and lymphoma.
Researchers at the University of Georgia have discovered a drug combination that targets mitotic slippage, allowing for complete cell death and improving chemotherapy's effectiveness. The study focuses on inactivating CRL2-ZYG11, which promotes mitosis, and has potential to treat various cancers.
Researchers at Uppsala University developed a new approach to study cancer cells' reactions to treatments, enabling the identification of promising drug combinations. 3D tumor models mimic real-world conditions, where cancer cells have limited access to nutrients and oxygen.
Researchers discovered CD98 promotes AML, a type of aggressive cancer, and inhibiting it with the anti-CD98 antibody IGN523 blocks AML growth in patient-derived cells and mouse models.
Researchers found thousands of genetic translocations in both healthy and cancerous mouse cells, highlighting the importance of considering individual genetic backgrounds. By using 'de novo assembly', scientists can compare a patient's cancer cells to their own healthy cells, reducing errors in translocation discovery.
Researchers have broken down lung cancer into distinct subtypes with unique molecular profiles, suggesting potential for personalized therapies. The study identifies specific subsets of cancer cells that may be responsive to immunotherapy, a promising approach for treating the disease.
Researchers develop universal assay to detect cisplatin cross-linking sites in the genome. They found that mitochondrial DNA is a major target of cisplatin's action, while nuclear DNA is less affected.
Researchers use fission yeast to discover new cancer drugs targeting active proteins involved in DNA replication. The unique "arched and snapped" appearance of treated cells suggests potential for accelerating drug development.
Scientists at TUM have discovered new mechanisms of action for Imiquimod, a medication used to treat viral skin infections and certain types of skin cancer. The study reveals that Imiquimod activates the NLRP3 inflammasome, which can lead to inflammation and potentially contribute to its efficacy or adverse side effects.
A new treatment plan combining multiple targeted drugs for CML has the potential to increase life expectancy and reduce relapse risk. Mathematical modeling predicts optimal combination schedules based on tumor mutations, offering a personalized approach to cancer treatment.
Researchers found a way to break up p97 complex into its subunits using ASPL protein, which could be a promising new approach to kill proliferating cancer cells. This discovery may lead to the identification of smaller molecules that can disrupt the structure of p97 in a targeted manner.
Researchers identified amino acid valine as crucial for hematopoietic stem cell maintenance. A valine-free diet with gradual reintroduction led to successful long-term engraftment of healthy donor cells in mice.
Researchers used CRISPR to identify genes essential for AML cell survival, including the novel KAT2A gene. Inhibition of KAT2A destroys AML cells while sparing healthy blood cells in laboratory and mouse studies, offering new potential treatment options.
Researchers discovered that leukemia cells don't hide in specific niches but instead move actively throughout the bone marrow. This movement may help them survive treatment and evade targeted therapies.
Quiescent human cells exhibit an inflammatory profile similar to acute infections when energetically stressed, suggesting a pro-survival strategy may not be well-suited for long-term chronic stresses. This could impair genome repair and increase cancer risk.
Researchers will study cellular and molecular mechanisms of lung regeneration, targeting AT2 cells with gene editing techniques to correct disease-causing mutations and promote repair.
Researchers pinpoint a unique metabolic reprogramming in cancer cells that enables their ability to biosynthesize and replicate, and may provide new treatment opportunities. By blocking specific enzymes involved in this process, tumor growth can be slowed or stopped in preclinical tests.